Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DWP450 for Crows Feet Lines
NCT02882893Phase 3Unknown
- Sponsor
- Daewoong Pharmaceutical
- Start
- Aug 2016
- Primary completion
- Jan 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of prabotulinumtoxinA in Crow's feet (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoint: Facial Wrinkle Scale severity of Crow's feet lines at 4 weeks. Status: unknown.
02
Drugs
prabotulinumtoxinA
03
Conditions
Crow's feet
Beyond the preview
Go deeper on NCT02882893.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02882893.